Companies
Novogene
a sequencing and bioinformatics CRO serving over 7,300 customers across about 90 countries, with 547 registered software copyrights.
- Country
- China
- Ticker
- SSE: 688315
CAP/CLIA
ISO 9001
Coverage
| CN | EU | US | |
|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $75 million Series B financing (515 million RMB) and 200 million RMB Series A financing (2016-11-30) | biospace.com · novogene.com |
| Certification | CAP, ISO 13485, ISO 17025, and CLIA certifications (2025-12-31) | stockmc.xueqiu.com · biospace.com · novogene.com |
| Regulatory approval | CFDA approval for NovoFocus NSCLC CDx Test and Digital PCR NG biochip scanner; 2018 NMPA approval for high-throughput sequencing tumor gene detection kit (2024-01-01) | stockn.xueqiu.com · novogene.com |
| Production site | Laboratories or experimental bases in Beijing, Tianjin, Nanjing, Guangzhou, Shanghai (China); United States (Sacramento, Beaverton), United Kingdom (Cambridge), Germany, Singapore, and Japan (2025-12-31) | static.cninfo.com.cn · sapac.illumina.com · stockmc.xueqiu.com · biospace.com |
| Headcount | over 1,000 employees (technical and management team) (2025-12-31) | static.cninfo.com.cn · stockmc.xueqiu.com |
| Revenue | 2.2096 billion RMB (2025 annual revenue) (2025-12-31) | static.cninfo.com.cn · stockmc.xueqiu.com |
Independent sources: biospace.com · sapac.illumina.com · static.cninfo.com.cn · stockmc.xueqiu.com · stockn.xueqiu.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bioinformatics & multi-omics | bioinformatics-omics | Low | → |
| Metabolomics (service) | bioinformatics-omics | Low | → |
| Single-cell omics | bioinformatics-omics | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.